You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

July 15, 2013

Thailand to Crack Down on Illegal Online Pharmacies

E-Commerce Law & Policy

International headlines recently focused on a dramatic case of regulatory enforcement against an online pharmacy. The Pittsburgh Post-Gazette reported that a 33-year-old Thai woman was running a company with the website www.eDrugnet.com, along with at least 30 other affiliated websites. These sites sold drugs without prescriptions, despite the fact that prescriptions were required in the purchasers’ country. These e-pharmacy websites were hosted in Thailand and shipped drugs to the United States. After receiving e-mails with drug orders from foreign customers, the company would send drugs overseas in boxes labeled as samples and gifts, via express mail.

After a lengthy investigation by the U.S. FDA, FBI, and Department of Homeland Security, which involved meeting the woman in Bangkok and ultimately causing her to fly to the United States to meet undercover agents, the woman confessed to the scheme. She pleaded guilty in a U.S. district court, and her websites have since been taken offline. On January 31, 2013, she was sentenced for wire fraud, money laundering, and introducing misbranded drugs into the United States. She has already agreed to pay the U.S. government US$2.1 million, reflecting the proceeds from her company’s drug sales, and the U.S. District Judge also added a US$5,000 fine to her sentence.

Online Pharmacies and Counterfeit Medicines

Given the millions of dollars involved in this case, it was bound to capture attention. This case highlights the efforts that government authorities are pursuing in order to reign in the rapid growth of online pharmacies. The authorities recognize that the sale of drugs online may offer certain advantages, but these are accompanied by potential dangers for consumer health and safety.

Online pharmacies can be beneficial in helping consumers find the specific drug products they need, and they often offer special discounts. Online pharmacies are also easy to access—a simple web search reveals a seemingly endless list of drugs that can be purchased on the web. Furthermore, if a customer feels embarrassed about purchasing a certain product (for example, erectile-dysfunction medication) from an actual pharmacy, using a virtual pharmacy can save the customer from an uncomfortable experience.

This is where the problems begin to arise. Online pharmacies often trade in counterfeit medicines that contain incorrect or inactive ingredients, thus creating potentially fatal risks for patients. The trade in counterfeit drugs has grown into a global industry worth billions of dollars, and these illegal activities have flourished on the internet.

Many online pharmacies focus their trade on specific product ranges that can be sold in a high volume online, with erectile-dysfunction (ED) drugs at the top of the list. A recent analysis and review of unregistered ED drugs seized by police and health authorities in Eastern Thailand found that most samples (88%) contained an amount of Active Pharmaceutical Ingredient (API) below the labeled claim, while some samples contained the wrong API altogether (e.g. chloramphenicol, an antibiotic). Apart from ED drugs, counterfeit abortifacient drugs, anti-obesity drugs, antimalarial drugs, and psycholeptic drugs have a high tendency to be sold illegally via e-commerce channels.

In Thailand, almost all of these counterfeit drugs are manufactured abroad and then smuggled into the country. These products are usually labeled “Made in Thailand” or show a Thai address. In general, the name and address are fake, and the manufacturers cannot be found in the records of the Thai FDA’s pharmaceutical manufacturing database.

Combating the Problem through Regulation

Despite the boom in online sales of drugs, Thailand does not yet have separate legislation governing the online sale of pharmaceutical products through e-pharmacies hosted in the Kingdom. Currently, the online sales of these products are governed by the Drug Act B.E. 2510 (1967), which broadly covers physical sales of medicinal and pharmaceutical products.

According to Section 14 of the Drug Act, the Thai FDA, as the licensing authority, will approve a “license to sell drugs” for business operators if they comply with certain requirements. One of the requirements is that business operators resident in Thailand must have the appropriate premises to sell or store drugs, with the appropriate equipment for use in the sale or storage of drugs, and control over the maintenance of drug quality and quantity, as prescribed in the Ministerial Regulations. In addition, Section 21 of the Drug Act states that a business operator that has been permitted to sell modern drugs must have a pharmacist on duty during business hours.

These two sections of the Drug Act forbid the distribution of drugs “virtually,” since neither the requirement of appropriate premises nor that of an on-duty pharmacist would be satisfied by an online operation.

Restrictions on Drug Advertising

Despite the fact that it is illegal under Thai law to market drug products online, many online pharmacies are using social-media marketing as a promotional channel to attract customers and sell them illicit medicines and psychotropic substances. Many pharmacies are creating fan pages via social media as part of “direct-to-consumer advertising” strategies. This can put many people at a greater risk of buying and using dangerous products.

With regard to online advertising, while there are no specific rules on the use of the internet or social media for drug advertisements, the Thai FDA enforces and regulates the promotion of drugs via Sections 88 to 90 of the Drug Act. Under Section 88 bis, businesses that advertise drugs via radio, television, movies, or through printed matter must receive permission from the Thai FDA for the text, sound, and/or picture(s) used in their advertisement(s).

Nevertheless, according to the Thai FDA, most online advertisements (more than 85%) are being presented without permission. Currently, the FDA has made it a priority to deal with this problem. Thus, business operators must ensure that their social-media marketing strategies meet Thai FDA requirements, as well as the requirements of the Drug Act. Any violation of the Drug Act’s marketing provisions is subject to a fine of up to THB 100,000 (US$3,340).

Increasing International and Local Enforcement

Coupled with the increase in regulatory enforcement, government authorities are taking other aggressive actions against online pharmacies and counterfeit medicines both internationally and locally. According to a report of the World Health Organization (WHO), over half of the medicines from illegal internet pharmacies are counterfeit. In order to fight against this phenomenon, the WHO set up the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) in 2006. IMPACT has led international actions, offering guidance on how to strengthen legislative and regulatory frameworks. Through IMPACT, the WHO has worked with regulatory agencies such as Interpol to uncover counterfeit operations.

In 2010, Operation Pangea III, coordinated by Interpol and IMPACT, collated data from 45 participating countries and uncovered a vast network of counterfeit drug sales on the internet. The operation revealed 694 websites engaged in illegal activities, 290 of which have now been shut down. One of the first coordinated operations, Storm II, successfully targeted 8 countries across Southeast Asia, including Thailand. The operation led to the seizure of 20 million fake medicines, including antibiotics, antimalarial and birth control tablets, tetanus serums, aspirin, and ED drugs.

Building on this international cooperation, the Thai FDA has established the Center for Combating Counterfeit Drugs. This center engages consumers in the broader enforcement effort by encouraging tipsters to provide information about counterfeit medicines to government authorities (via [email protected]).

Looking Ahead

Thailand’s current drug laws were established more than 40 years ago and are therefore ill suited to deal with e-commerce. A draft bill to replace the current Drug Act is now being discussed, but like its predecessor, the current draft remains silent on the issue of online pharmacies or the online trade of drugs. The new draft law does mention the imposition of civil liability, which could apply to e-commerce Drug Act violators. Through additional civil liability, legislators have sought to increase compensation for victims of drugs sold in violation of the Drug Act.

Will civil liability be enough to quell the perpetration of online trading or e-commerce in medicines? Given how difficult it is to identify the operators of online pharmacies, there are doubts about whether the enactment of the new draft law will do much to alleviate the damage resulting from online drug purchases.

As an alternative, Thai law may prioritize preventing these adverse results by imposing regulations directly on online pharmacies and distributors of pharmaceutical products, as such regulations could be much more effective than merely compensating victims after the fact.

RELATED INSIGHTS​ 

June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
June 4, 2026
Indonesia’s Minister of Health has issued Decree No. HK.01.07/MENKES/301/2026 on the Affixation of Nutritional Labels and Health Information to Ready-to-Eat Processed Food Products. The decree came into force on April 14, 2026, and was issued to implement the Health Law and Minister of Health Regulation No. 3 of 2026 on Disease Control. The decree requires the inclusion of Nutri-Level labeling on the front-of-pack nutrition labeling (FOPNL) to indicate the product’s nutritional level based on the content of sugar, salt, and fat (“gula, garam dan lemak (GGL)”). Changes from 2024 Draft Regulation The Nutri-Level labeling was previously proposed in 2024 by the Indonesian FDA (BPOM) through a draft regulation concerning nutrition information. While the categories of Nutri-Level labeling remain the same in the issued decree, the content requirements of sugar, salt and fat in the decree are different from the earlier proposal introduced in the 2024 draft BPOM regulation. In addition, the decree has further specified that the content of fat in the Nutri-Level labeling is the content of saturated fat, not total fat as previously proposed in the 2024 draft. The decree requires Nutri-Level labeling to be implemented in beverage products, which is the same as previously proposed in the 2024 draft BPOM regulation. Other food products may gradually become subject to mandatory Nutri-Level labeling under future implementing regulations. Nutri-Level Labeling Food levels as shown by the Nutri-Level labeling are classified into four color-coded categories from A to D: Level A (lowest amount) in dark green Level B in light green Level C in yellow Level D (highest amount) in red The Nutri-Level labeling is represented by the following image. The requirements for each level for sugar, salt, and fat content, based on amounts per 100 milliliters of product in beverage form, are as follows. Nutri-Level information must be
May 29, 2026
Indonesia’s Food and Drug Authority (BPOM) has issued Regulation No. 7 of 2026 on Drug Promotion and Advertising, establishing an updated framework for promotional activities involving medicinal products in Indonesia. The regulation took effect on April 16, 2026, and supersedes BPOM Regulation No. 2 of 2021 on Drug Advertising Supervision. The new regulation maintains general principles for advertising content, including requirements that advertisements be objective, complete, and not misleading, as further detailed in its annex. It also confirms that advertisements for nonprescription drugs directed to the public must obtain prior approval from BPOM before publication and must be in Bahasa Indonesia. The regulation provides a more comprehensive framework governing how drug promotion is conducted, introducing several notable additions and changes, as described below. Procedure and Requirements for Drug Advertisement Approval To apply for a drug advertisement approval, applicants must create an online account through the dedicated portal SIAPIK. Advertisement approval is available only for registered drugs; unregistered drugs are not eligible for advertisement approval with BPOM. The application must include the advertisement design, along with a translation if the design contains any wording in a foreign language. The submission format varies by media type, requiring, for example, copies in the form of print advertisements for visual media, scripts for audio media, and storyboards for audiovisual media. For online media—including social media—submissions should include any captions, descriptions, and hashtags that form an integral part of the advertising material. The approval timeline takes approximately 3–4 months, as BPOM will generally request additional information or revisions during the verification and evaluation process. Applicants have 20 days to submit any such requested documents. BPOM may also conduct a reevaluation of advertisements that have already received approval, based on monitoring results or new information regarding the safety and quality of the advertised drug. This